急性陰道念珠菌病治療的全球市場：藥物類型、給藥途徑、分銷渠道、區域規模、份額、前景、機會分析（2022-2028 年）

市場公司致力於拓展其產品組合、加強其在全球市場中的地位以及預計將在預測期內推動全球市場增長的收購等無機活動。此外，外陰陰道念珠菌病治療開發的研發力度加大，預計將在預測期內推動全球急性外陰陰道念珠菌病治療市場的增長。

本報告研究和分析了全球急性外陰念珠菌病治療市場，並提供了市場概況、市場動態、趨勢、競爭形勢和企業概況等系統信息。

目錄

第 1 章調查目標/先決條件

第二章市場概述

• 報告說明
  • 市場定義和範圍
• 執行摘要
  • 市場細分：按藥物類型
  • 市場細分：按管理途徑
  • 市場細分：按分銷渠道
  • 市場細分：按地區
• 連貫的機會圖 (COM)

第三章市場動態/監管/趨勢分析

• 市場動態
  • 促進因素
  • 抑制器
  • 市場機會
• 影響分析
• 流行病學
• 主要發展
• 監管場景
• 兌換場景
• PEST 分析
• 市場份額分析
• 品牌分析

第 4 章全球急性外陰念珠菌病治療市場：冠狀病毒 COVID-19 大流行影響

• COVID-19 期間的市場狀況
• 供給側分析/需求側分析
• COVID-19 對急性外陰念珠菌病治療市場的影響
• 政府應對 COVID-19 的舉措

第 5 章全球急性外陰念珠菌病治療市場：按藥物類型（2017-2028 年）

• 簡介
• 克黴唑
• 制黴菌素
• 氟康唑
• 酮康唑
• 特比□芬
• 特康唑
• 其他

第 6 章全球急性外陰念珠菌病治療市場：按給藥途徑（2017-2028）

• 簡介
• 口語
• 靜脈注射
• 本地

第 7 章全球急性外陰念珠菌病治療市場：按分銷渠道（2017-2028 年）

• 簡介
• 院內藥房
• 零售藥店
• 網上藥店

第 8 章全球急性外陰念珠菌病治療市場：按地區（2017-2028 年）

• 簡介
• 北美
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章競爭態勢

• 公司簡介
  • Mycovia Pharmaceuticals, Inc.
  • Scynexis, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, SA
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc
  • Amplyx Pharmaceuticals Inc.,
  • Pfizer, Inc.
• 分析師見解

第10章 章節

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.

Market Dynamics

Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2022, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.

Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-γ, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.

Key features of the study:

• This report provides an in-depth analysis of global acute vulvovaginal candidiasis treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market

Detailed Segmentation:

• Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
  • Oral
  • Intravenous
  • Topical
• Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Vulvovaginal Candidiasis Treatment Market, By Region:
  • North America
• By Country
  • U.S.
  • Canada
• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
• By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
• By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
• By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Company Profiles
• Mycovia Pharmaceuticals, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
• Scynexis, Inc.
• Basilea Pharmaceutica Ltd.
• Astellas Pharma Inc.
• Grupo Ferrer Internacional, S.A.
• Pacgen Life Science Corporation
• NovaDigm Therapeutics, Inc.
• Cidara Therapeutics, Inc.
• Amplyx Pharmaceuticals Inc.
• Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Epidemiology
• Key Developments
• Regulatory Scenario
• Reimbursement Scenario
• PEST Analysis
• Market Share Analysis
• Brand Analysis

4. Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus COVID - 19 Impact

• During COVID-19 Market Situation
• Supply Side and Demand Side Analysis
• Impact of COVID-19 on Acute Vulvovaginal Candidiasis Treatment Market
• Government Initiatives to Combat COVID-19

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Clotrimazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Nystatin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Fluconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Ketoconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Terbinafine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Terconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

9. Competitive Landscape

• Company Profiles
  • Mycovia Pharmaceuticals, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Scynexis, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Basilea Pharmaceutica Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Astellas Pharma Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Grupo Ferrer Internacional, S.A
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Pacgen Life Science Corporation
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • NovaDigm Therapeutics, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Cidara Therapeutics, Inc
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Amplyx Pharmaceuticals Inc.,
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About us and Sales Contact